Comparative Analysis of Health Care Use and Costs for Orthobiologic versus Surgical Treatments in Economically High-Impact Knee Conditions

This retrospective, propensity-matched study of commercially insured patients demonstrates that orthobiologic treatments (PRP and BMAC) for degenerative meniscal tears and knee osteoarthritis result in similar or lower downstream healthcare costs and utilization compared to surgical alternatives, with low rates of subsequent surgery over a four-year period.

The Gist

Imagine your knee is like a car engine that's starting to make a loud grinding noise. For decades, the standard mechanic's advice has been: "If it's broken, replace the whole engine (Total Knee Replacement) or take out the broken part (Meniscectomy)." These are big, expensive, and invasive repairs.

But recently, a new type of mechanic has emerged offering "tune-ups" using special oils and fluids (Orthobiologics like PRP and BMAC) to try to heal the engine from the inside out. The big question for patients and insurance companies has been: Do these tune-ups actually work, and do they save money compared to the big engine replacement?

This study is like a massive, real-world test drive comparing these two approaches.

The Big Race: Surgery vs. The "Healing Juice"

The researchers set up two different races to see which path was cheaper and less stressful for the patient in the long run.

Race 1: The "Engine Replacement" vs. The "Stem Cell Tune-Up"

• The Contenders: Patients with worn-out knees (Osteoarthritis) were split into two groups. One group got the big surgery (Total Knee Replacement). The other group got an injection of BMAC (a concentrate of their own stem cells and healing factors) mixed with PRP (Platelet-Rich Plasma, essentially super-charged blood).
• The Result: The surgery group had to pay a huge toll to get through the next two years. They needed more physical therapy, more X-rays, and more painkillers. The "Tune-Up" group spent significantly less money overall.
• The Surprise: Many people thought that if you got a "tune-up," you'd eventually need the "engine replacement" anyway. But in this study, very few people who got the injection ended up needing the big surgery within two years. It was like the tune-up actually kept the car running well enough to avoid the expensive replacement.

Race 2: The "Part Removal" vs. The "Platelet Patch"

• The Contenders: Patients with a torn piece of cartilage (meniscus) but not severe arthritis. One group had the torn piece surgically shaved off (Meniscectomy). The other group got a PRP injection to help it heal.
• The Result: This race was much closer. The costs were roughly the same, or slightly lower for the injection group depending on how you counted the bills.
• The Catch: The injection group actually used more painkillers (opioids) than the surgery group. It seems the surgery group felt better faster, but the injection group had to manage the pain a bit longer while their body healed. However, the injection group didn't need as much physical therapy.

The "Hidden Costs" Analogy

Think of the surgery like buying a brand-new, expensive car. You pay a lot upfront, but then you have to keep paying for insurance, gas, and maintenance (physical therapy, follow-up visits) for years.

The injection is like buying a high-quality repair kit. The upfront cost might be similar or slightly lower, but the "maintenance" costs (visits, scans, meds) were generally lower because the body did more of the work on its own.

The Verdict in Plain English

1. For Worn-Out Knees (Arthritis): The "Stem Cell Tune-Up" (BMAC/PRP) is a cheaper alternative to replacing the whole knee. It saves money on hospital stays, physical therapy, and pain meds. Plus, most people didn't need the big surgery later on.
2. For Torn Cartilage (Meniscus): The "Platelet Patch" (PRP) is just as good or slightly cheaper than shaving off the torn part. It's a valid option that avoids the risks of surgery.
3. The "Do-Over" Myth: A common fear was that if you try the injection first, you'll just end up paying for the injection and then the surgery. This study says: No. Most people who got the injection stayed on that path and didn't need the surgery within the first two years.

The Bottom Line

If you have a knee problem, this study suggests that for many people, trying the "healing injection" first isn't just a gamble; it's a smart financial and health move. It often costs less, involves less downtime, and rarely forces you to go back and get the big surgery later.

Important Note: The study authors are honest that this is a "preprint" (a draft before final peer review) and that these results apply best to people with degenerative wear-and-tear (like an old car), not necessarily young athletes with fresh, traumatic injuries. But for the average person with a grinding knee, the "tune-up" looks like a very promising option.

Technical Summary

1. Problem Statement

Total knee arthroplasty (TKA), partial knee arthroplasty (pKA), and arthroscopic meniscectomy are among the most frequently performed orthopedic procedures in the US. However, their utilization faces increasing scrutiny regarding overuse, variable clinical benefit (particularly for degenerative meniscal tears and early-stage osteoarthritis), and high associated costs. Conversely, orthobiologic therapies—specifically Platelet-Rich Plasma (PRP) and Bone Marrow Aspirate Concentrate (BMAC)—have emerged as less invasive alternatives. While preliminary evidence suggests clinical efficacy, there is a lack of rigorous, real-world data comparing the downstream health care resource utilization (HCRU) and total costs of orthobiologics versus surgical interventions. Payers and clinicians need evidence to determine if orthobiologics represent a cost-saving alternative or if they merely shift costs to repeat injections and subsequent imaging without preventing eventual surgery.

2. Methodology

The study employed a retrospective, observational cohort design using linked data from a nationwide commercial insurance provider and the Regenexx patient registry (2016–2023).

• Study Populations: Two distinct comparisons were analyzed:
  1. PRP vs. Meniscectomy: Patients with degenerative meniscal pathology and minimal osteoarthritis.
  2. BMAC/PRP vs. TKA/pKA: Patients with knee osteoarthritis.
• Data Linkage: Procedural data from the Regenexx registry were linked to commercial claims data using a privacy-preserving token-based method (Datavant, Inc.).
• Eligibility: Patients were aged ≥18, had continuous commercial coverage for 12 months pre- and post-procedure, and met specific diagnostic criteria. Exclusions included inflammatory syndromes, infections, prior knee surgery, and recent corticosteroid use.
• Statistical Approach:
  • Propensity Score Matching (PSM): To minimize selection bias, 1:10 greedy matching was used to balance demographic and clinical confounders (e.g., age, comorbidities, prior interventions, health-seeking behavior) between the orthobiologic and surgical groups.
  • Outcomes:
    • Co-primary: Total health care costs at 12 and 24 months.
    • Exploratory: Costs and HCRU at 36 and 48 months.
    • HCRU Metrics: Outpatient visits, physical therapy (PT), imaging (X-ray, MRI), opioid use, repeat injections, and subsequent surgery.
  • Costing Models: Costs were estimated using three approaches:
    1. Medicare-based estimates (bundled payments for surgery).
    2. Private payer estimates (commercial allowed amounts).
    3. Aggregate/Truncated methods (summing actual claims, with outliers truncated at the 5th/95th percentile).

3. Key Contributions

• Real-World Evidence: This is one of the first large-scale studies to directly compare downstream costs and utilization of orthobiologics against standard surgical care using linked registry and claims data.
• Longitudinal Analysis: The study extends beyond the typical 12-month window, providing data up to 48 months, which is critical for assessing the durability of orthobiologic treatments.
• Multiple Costing Frameworks: By applying Medicare, commercial, and aggregate costing methods, the study tests the robustness of findings across different payer perspectives.
• Addressing the "Surgery Conversion" Myth: The study specifically tests the hypothesis that orthobiologic treatment inevitably leads to higher downstream costs due to eventual conversion to surgery, finding this not to be the case in the studied cohorts.

4. Results

After propensity matching, the study analyzed 167 PRP patients (matched to 1,670 meniscectomy patients) and 165 BMAC/PRP patients (matched to 1,650 TKA/pKA patients).

A. Health Care Resource Utilization (HCRU)

• BMAC/PRP vs. TKA/pKA:
  • Surgery Conversion: Progression to TKA/pKA after BMAC/PRP was rare (<11 events, suppressed) at 12 and 24 months.
  • Utilization: The BMAC/PRP group had significantly lower rates of outpatient visits, physical therapy, knee X-rays, and opioid use compared to the surgical group at 12 and 24 months.
  • Imaging: MRI usage was higher in the BMAC/PRP group (likely for monitoring), while X-ray usage was significantly lower (94% in surgery vs. 15% in BMAC at 12 months).
• PRP vs. Meniscectomy:
  • Surgery Conversion: Rates of subsequent meniscectomy after PRP were below the suppression limit (<11 events).
  • Utilization: Differences were modest. PRP patients had fewer PT visits at 12 months but higher opioid use at both 12 and 24 months compared to meniscectomy patients.

B. Cost Outcomes

• BMAC/PRP vs. TKA/pKA:
  • Surgery was consistently more expensive across all costing methods.
  • At 12 months, the mean cost difference ranged from $13,556 (commercial payer) to $39,913 (external inflated costs) in favor of BMAC/PRP.
  • At 24 months, the savings persisted, with differences ranging from $11,796 to $36,727.
• PRP vs. Meniscectomy:
  • Results were mixed depending on the costing model.
  • Using Medicare estimates, costs were statistically similar ($4 difference at 12 months).
  • Using Commercial payer and Aggregate estimates, meniscectomy was more expensive, with PRP saving approximately $1,500–$2,600 at 12 and 24 months.

C. Long-Term Trends (36–48 Months)

• Exploratory analyses showed that the pattern of lower subsequent surgery rates and generally lower cumulative costs for orthobiologics persisted through 48 months, though sample sizes for continuous enrollment decreased.

5. Significance and Implications

• Economic Viability: The findings challenge the assumption that orthobiologics are a "bridge" to expensive surgery that increases total system costs. Instead, for appropriately selected patients (degenerative meniscal tears and moderate osteoarthritis), orthobiologics appear to be a cost-saving or cost-neutral alternative to surgery.
• Clinical Decision Making: The low rate of progression to surgery (rarely exceeding 10-15% even in long-term follow-up) supports the use of orthobiologics as a primary intervention rather than a last resort.
• Policy and Payer Strategy: These results provide evidence for payers to reconsider coverage policies for PRP and BMAC, potentially reducing the financial burden on health systems associated with high-volume, high-cost surgical procedures.
• Limitations: The study acknowledges potential selection bias (patients choosing orthobiologics may differ in unmeasured ways), the lack of patient-reported outcome measures (PROs), and the reliance on claims data which may underreport certain adverse events or indirect costs (e.g., lost wages).

Conclusion: In this real-world, propensity-matched analysis, orthobiologic treatments (PRP and BMAC) were associated with similar or lower downstream health care costs and resource use compared to surgical alternatives for degenerative knee conditions, with low rates of subsequent surgery over a 4-year period.